The company said a phase 3 study evaluating its influenza vaccine candidate, mRNA-1010—which utilizes the same messenger ribonucleic acid (mRNA) platform as its COVID-19 vaccine—showed positive effectiveness.

In the trial, which featured 40,805 participants and compared mRNA-1010 to an existing seasonal flu vaccine in adults aged 50 and up, the relative protection from the candidate was 26.6 percent better. In a subgroup analysis among participants aged at least 65, the relative efficacy was 27.4 percent.

“Today’s strong Phase 3 efficacy results are a significant milestone in our effort to reduce the burden of influenza in older adults,” Stéphane Bancel, Moderna’s CEO

https://www.zerohedge.com/medical/moderna-ask-clearance-combination-covid-influenza-vaccine

 

Big test for RFKjr’s team — where are the safety tests for the COVID portion?? How can they possibly approve ANY new COVID shot when the results to date have been @ bioweapon levels??